🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thrilled to present our study on epigenomic & genomic convergence in tumor evolution on the TRACERx cohort with Nnennaya Kanu and Charles Swanton : DNA methylation co-operates with genomic alterations during NSCLC evolution. Huge thanks to #MAP2024 for awarding us best poster!

🔵 ¿Qué desafíos enfrenta la biopsia líquida? Descúbrelo en nuestra mesa redonda con expertos como la Dra. Ana Vivancos del Vall d’Hebron Institute of Oncology (VHIO) y la Dra. Noelia Tarazona de INCLIVA. Las esperamos en #SimposioBiopsiaLíquida ¡Inscríbete ahora! 👉 tacticsmd.net/congreso/liqui…

🚨 Just out in Annals of Oncology! 🌊 Dive into the latest on liquid biopsy for colorectal cancer🩸: What’s the best approach to monitor ctDNA? Tumor-informed vs. tumor-agnostic strategies for minimal residual disease detection. 📄Read here: [annalsofoncology.org/article/S0923-…]

📢New review in press: Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy Andres Cervantes doi.org/10.1016/j.anno…

Excited to share my doctoral thesis on luminal metastatic breast cancer treated with CDK4/6i, now published in European Journal of Cancer. Thanks to Eva M Ciruelos & Aleix Prat #PrecisionOncology for their invaluable support as well as SOLTI #cancerresearch #BreastCancer ejcancer.com/article/S0959-…

I am very proud to have presented my work at the X Liquid Biopsy Symposium, which focused on WES ctDNA analysis to reveal relapse mechanisms and potential therapeutic targets in colon cancer🩸👨‍💻 Tactics INCLIVA #SimposioBiopsiaLíquida #CRCteam

🚀 Daniel González Camblor presenting the METACC Study at the CIBERONC session in Seville! 🔬 Exciting preliminary results on metastatic colon cancer and resistance. #CancerResearch #METACC

What makes HR+/HER2− breast cancer in very young women (≤35 years) different from older patients? In our recent study published in @CancerComm, we explored the transcriptomic landscape of this underrepresented group. doi.org/10.1002/cac2.7… #BreastCancer #YoungWomen

🔥Just out in Nature Cancer! ✅ TAV16, our tumor-agnostic WES-based assay, ranks among the best for MRD detection. ✅ Immune evasion as the main driver progression in MSS CRC, opening new avenues for ICIs. 🙏SEOM Grupo Español de Tratamiento de Tumores Digestivos Instituto de Salud Carlos III (ISCIII) Hospital Clínic de València nature.com/articles/s4301…

Esta investigación del INCLIVA, que logra avances para seguir investigando en posibles inmunoterapias contra el cáncer de colon, ha recibido financiación del #ISCIII en la convocatoria de Proyectos de Investigación (PI), como parte de la Acción Estratégica en Salud (AES).

Now the incredible Mariam Jamal-Hanjani presenting data from the TRACERx Peace cohorts defining the metastatic cascade in Nsclc ⁦Science and Innovation at Cancer Research UK⁩ ⁦UCL Cancer Institute⁩ ⁦The Crick⁩

Una investigación liderada por el Hospital Clínico de Valencia mejora la detección de micrometástasis del cáncer de colon ver.tw/auqb12

📌Queremos agradecer sinceramente a T5 por hacerse eco de la publicación de nuestro estudio, y muy especialmente a las periodistas Isabel Jiménez y Clara Marzá por su interés y sensibilidad al compartir este avance científico. 🙏

Un test ideado en España permite detectar qué pacientes de cáncer de colon recaerán tras la cirugía elperiodico.com/es/sanidad/202… a través de El Periódico

Nuevo avance científico marca España: un test de sangre permitirá detectar el riesgo de recaída del cáncer colorrectal ver.tw/dcwrq2

👏 Amazing discussion by Noelia Tarazona & colleagues in today’s #ASCO25 session: 🩸”ctDNA Guiding Treatment of Colorectal Cancer: Ready for Primetime?” 💡Insightful take on how liquid biopsy is reshaping CRC treatment decisions. #CRC #ctDNA #PrecisionOncology 🔬

🧬 9 investigadores a los que financiamos el doctorado han sido seleccionados para participar en #EJIC2025, el encuentro de jóvenes investigadores en cáncer organizado por @aeccZaragoza.👇 ▪️Eduardo Aranda Cañada (#ContraCáncerAragón), ▪️ Pablo Martín García (Asociación Contra el Cáncer Asturias),

💥Proud of our team for presenting cutting-edge work on ctDNA🩸and tumor-immune profiling in CRC at #EACR2025! 🔬From resistance mechanisms to new immunotherapy strategies - science made in Valencia INCLIVA 🇪🇸✨ 🔝Belén Martínez Castedo Daniel González Camblor Blanca García Micó

🔥 We got the cover of the June issue of Nature Cancer with our paper! 🌟 A huge honor and a recognition of the team’s hard work. 🔗 lnkd.in/dd6dE7A4 📄 See lnkd.in/dfd3hfi2